[go: up one dir, main page]

WO2018102594A8 - Methods of treating solid tumors with anti-cd200 antibodies - Google Patents

Methods of treating solid tumors with anti-cd200 antibodies Download PDF

Info

Publication number
WO2018102594A8
WO2018102594A8 PCT/US2017/064033 US2017064033W WO2018102594A8 WO 2018102594 A8 WO2018102594 A8 WO 2018102594A8 US 2017064033 W US2017064033 W US 2017064033W WO 2018102594 A8 WO2018102594 A8 WO 2018102594A8
Authority
WO
WIPO (PCT)
Prior art keywords
solid tumors
antibodies
methods
treating solid
treating
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2017/064033
Other languages
French (fr)
Other versions
WO2018102594A1 (en
Inventor
Xiaoping Zhang
Wei-jian PAN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alexion Pharmaceuticals Inc
Original Assignee
Alexion Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alexion Pharmaceuticals Inc filed Critical Alexion Pharmaceuticals Inc
Publication of WO2018102594A1 publication Critical patent/WO2018102594A1/en
Publication of WO2018102594A8 publication Critical patent/WO2018102594A8/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

The present disclosure provides methods for treating solid tumors using an effective amount of an anti-CD200 antibody, or antigen-binding fragment thereof.
PCT/US2017/064033 2016-12-01 2017-11-30 Methods of treating solid tumors with anti-cd200 antibodies Ceased WO2018102594A1 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201662428838P 2016-12-01 2016-12-01
US62/428,838 2016-12-01
US201762466224P 2017-03-02 2017-03-02
US62/466,224 2017-03-02

Publications (2)

Publication Number Publication Date
WO2018102594A1 WO2018102594A1 (en) 2018-06-07
WO2018102594A8 true WO2018102594A8 (en) 2018-07-26

Family

ID=61022406

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2017/064033 Ceased WO2018102594A1 (en) 2016-12-01 2017-11-30 Methods of treating solid tumors with anti-cd200 antibodies

Country Status (1)

Country Link
WO (1) WO2018102594A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019067499A1 (en) 2017-09-27 2019-04-04 Alexion Pharmaceuticals, Inc. Biomarker signature for predicting tumor response to anti-cd200 therapy
US11802154B2 (en) 2017-12-20 2023-10-31 Alexion Pharmaceuticals, Inc. Humanized anti-CD200 antibodies and uses thereof
US12139533B2 (en) 2017-12-20 2024-11-12 Alexion Pharmaceuticals, Inc. Liquid formulations of anti-CD200 antibodies

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
WO1988006630A1 (en) 1987-03-02 1988-09-07 Genex Corporation Method for the preparation of binding molecules
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
ATE164395T1 (en) 1990-12-03 1998-04-15 Genentech Inc METHOD FOR ENRICHMENT OF PROTEIN VARIANTS WITH MODIFIED BINDING PROPERTIES
US5780279A (en) 1990-12-03 1998-07-14 Genentech, Inc. Method of selection of proteolytic cleavage sites by directed evolution and phagemid display
WO1992015677A1 (en) 1991-03-01 1992-09-17 Protein Engineering Corporation Process for the development of binding mini-proteins
US5508717A (en) 1992-07-28 1996-04-16 Sony Corporation Computer pointing device with dynamic sensitivity
JP4436457B2 (en) 1995-08-18 2010-03-24 モルフォシス アイピー ゲーエムベーハー Protein / (poly) peptide library
US6090382A (en) 1996-02-09 2000-07-18 Basf Aktiengesellschaft Human antibodies that bind human TNFα
NZ512006A (en) 1996-02-09 2005-05-27 Abbott Biotech Ltd Medical treatment with human TNF-alpha antibodies
US7408041B2 (en) 2000-12-08 2008-08-05 Alexion Pharmaceuticals, Inc. Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof
AU2002246632B2 (en) 2000-12-08 2007-04-05 Alexion Pharmaceuticals, Inc. Chronic lymphocytic leukemia cell line and its use for producing an antibody
PT2463305T (en) * 2006-01-12 2016-07-19 Alexion Pharma Inc Antibodies to ox-2/cd200 and uses thereof
USRE46323E1 (en) * 2007-07-25 2017-02-28 Alexion Pharmaceuticals, Inc. Antibodies to OX-2/CD200 and uses thereof in inhibiting immune responses
CA2786692A1 (en) * 2010-01-11 2011-07-14 Alexion Pharmaceuticals, Inc. Biomarkers of immunomodulatory effects in humans treated with anti-cd200 antibodies
CA2789623A1 (en) 2010-02-11 2011-08-18 Alexion Pharmaceutical, Inc. Therapeutic methods using anti-cd200 antibodies
AR085141A1 (en) 2011-02-03 2013-09-11 Alexion Pharma Inc A METHOD FOR EXTENDING THE SURVIVAL OF A RENAL PAD, USE OF AN ANTIBODY ANTI-CD200 TO EXTEND THE SURVIVAL OF PADS

Also Published As

Publication number Publication date
WO2018102594A1 (en) 2018-06-07

Similar Documents

Publication Publication Date Title
ZA202311412B (en) Anti-phf-tau antibodies and uses thereof
WO2016062722A8 (en) Combination
PH12018502225A1 (en) Anti-il-33 antibodies, compositions, methods and uses thereof
EP3552665A3 (en) Antibodies
WO2018093821A8 (en) Dosing for treatment with anti-cd20/anti-cd3 bispecific antibodies
HK1259253A1 (en) Combination of an ox40 agonist and a 4-1bb agonist monoclonal antibody for treating cancer
WO2016191643A3 (en) Tigit-binding agents and uses thereof
HK1255604A1 (en) Anti-pd-l1 antibodies and uses thereof
CN110520441B8 (en) Anti-TGF-beta antibodies and uses thereof
MX2018006973A (en) Humanized anti-cd73 antibodies.
PH12016501366A1 (en) Novel anti-baff antibodies
WO2017218707A3 (en) Bispecific checkpoint inhibitor antibodies
AU2016219350A8 (en) Humanized anti-MUC1* antibodies
WO2016014688A3 (en) Anti-pd-1 antibodies
EA201890302A1 (en) CHEMICAL ANTIGEN RECEPTORS BASED ON SINGLE-DOMAIN ANTIBODIES AND METHODS OF THEIR APPLICATION
WO2017136659A3 (en) Humanized anti-cd3 antibodies, conjugates and uses thereof
WO2020051333A8 (en) Anti-avb8 antibodies and compositions and uses thereof
SG10201901057UA (en) Anti-pd-l1 antibodies
WO2015143123A3 (en) Antibodies against immunogenic glycopeptides, composition comprising the same and use thereof
WO2018031490A3 (en) Anti-ox40 binding proteins
PH12018502502A1 (en) Anti-gitr antibodies and uses thereof
WO2015010100A3 (en) Humanized antibodies with ultralong complementarity determining regions
MY189618A (en) Antibody specifically binding to pd-1 and functional fragment thereof
WO2018089807A3 (en) Anti-cd46 antibodies and methods of use
WO2018069871A3 (en) Anti-kras binding proteins

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 17833032

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase in:

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 17833032

Country of ref document: EP

Kind code of ref document: A1